PK Accelerator Bundled Solution Accelerates Pharmacokinetic Analysis and Reporting

Talk Will Cover the Use of Pharsight Software for In-Vitro / In-Vivo Correlation Modeling in Drug Development

Dr. Farkad Ezzet Will Present on the Strategic Value of Literature Modeling to Assess Disease Progression and Drug Attributes in Clinical Development

Dr. Laurent Claret Will Present Case Studies on the Value of Drug-Disease Modeling to Predict Efficacy and Survival Benefits of Anticancer Agents

Dr. Robert Leary Will Discuss Computational Methods for Model Evaluation; Dr. Mike Dunlavey Will Present Simplified Programming Approaches of Population Model User Interfaces

China Medicine became the first China biopharma to blame the worldwide economic crisis as a reason for lowering guidance; China Medical Technologies will pay $345 million for an HPV diagnostic test; Huifeng Bio-Pharmaceutical gained operational control of Xi'an Qinba Xintong Medical; Beike Biotechnology signed eight mutual cooperation agreements with other stem cell organizations; Pharsight has signed InforSense to distribute Pharsight’s clinical development management software in China; Shengtai Pharmaceutical received the China GMP certificate for its new glucose manufacturing facility; ProGenTech Limited in-licensed diagnostic technology from Human Genetic Signatures; a new article put the size of the domestic TCM market at more than 100 billion RMB ($14.7 billion) per year; and PricewaterhouseCoopers said China CROs booked $186 million in revenue during 2007. More details...

Stock Symbols: (OTCBB: CHME) (NSDQ: CMED) (OTCBB: HFGB) (NSDQ: PHST) (OTCBB: SGTI) (NYSE: WX)

Pharsight Corporation has signed a deal with InforSense under which InforSense will distribute Pharsight’s early stage clinical development management software in China. InforSense will be responsible for marketing and distribution, as well as end-user training, maintenance and support services. InforSense is based in London, though it has established a Shanghai office. Pharsight's software provides pharmacokinetic and pharmacodynamic (PK/PD) analysis and trial simulation, including support for reporting, archiving, and data visualization. More details...

Stock Symbol: (NSDQ: PHST)

Fears that Lehman Brothers may be the next bank to fail sparked a broad sell-off that sent the markets skidding to a sharply lower close with the Dow collapsing 280 points to 11,231. Nasdaq plummeted 60 points to 2210.

Tripos International will buy Pharsight Corp. for $57 million, the companies said Tuesday. (PHST)

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=3975058 for the full story.

China Medicine became the first China biopharma to blame the worldwide economic crisis as a reason for lowering guidance; China Medical Technologies will pay $345 million for an HPV diagnostic test; Huifeng Bio-Pharmaceutical gained operational control of Xi'an Qinba Xintong Medical; Beike Biotechnology signed eight mutual cooperation agreements with other stem cell organizations; Pharsight has signed InforSense to distribute Pharsight’s clinical development management software in China; Shengtai Pharmaceutical received the China GMP certificate for its new glucose manufacturing facility; ProGenTech Limited in-licensed diagnostic technology from Human Genetic Signatures; a new article put the size of the domestic TCM market at more than 100 billion RMB ($14.7 billion) per year; and PricewaterhouseCoopers said China CROs booked $186 million in revenue during 2007. More details... Stock Symbols: (OTCBB: CHME)[More...]